| Ms Rachel Elaine Hoevener, NP | |
|
225 S Pine St, Jmb, 2nd Floor, Seymour, IN 47274-2640 | |
| (812) 523-7466 | |
| (812) 523-7471 |
| Full Name | Ms Rachel Elaine Hoevener |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 225 S Pine St, Jmb, 2nd Floor, Seymour, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124794565 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 71011674A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inphynet Primary Care Physicians Midwest, S.c. | 6507808946 | 9 |
News Archive
The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc., and leading provider of healthcare information systems and connectivity solutions, today announced it has executed an agreement with Aunt Martha's Youth Service Center to deploy NextGen® EHR, NextGen® Practice Management and electronic dental records from Quality Systems.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 5 days ago
| Entity Name | Jackson County Schneck Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629143037 PECOS PAC ID: 8224004585 Enrollment ID: O20041029000584 |
News Archive
The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc., and leading provider of healthcare information systems and connectivity solutions, today announced it has executed an agreement with Aunt Martha's Youth Service Center to deploy NextGen® EHR, NextGen® Practice Management and electronic dental records from Quality Systems.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 5 days ago
| Entity Name | Inphynet Primary Care Physicians Midwest, S.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528090610 PECOS PAC ID: 6507808946 Enrollment ID: O20050525001352 |
News Archive
The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc., and leading provider of healthcare information systems and connectivity solutions, today announced it has executed an agreement with Aunt Martha's Youth Service Center to deploy NextGen® EHR, NextGen® Practice Management and electronic dental records from Quality Systems.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Rachel Elaine Hoevener, NP 225 S Pine St, Jmb, 2nd Floor, Seymour, IN 47274-2640 Ph: (812) 523-7466 | Ms Rachel Elaine Hoevener, NP 225 S Pine St, Jmb, 2nd Floor, Seymour, IN 47274-2640 Ph: (812) 523-7466 |
News Archive
The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc., and leading provider of healthcare information systems and connectivity solutions, today announced it has executed an agreement with Aunt Martha's Youth Service Center to deploy NextGen® EHR, NextGen® Practice Management and electronic dental records from Quality Systems.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
› Verified 5 days ago
Robin Elaine Cartwright, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 410 S Chestnut St, Seymour, IN 47274 Phone: 812-523-5185 | |
Mrs. Cathy Robbins Hildebrand, RN, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 411 W Tipton St, Seymour, IN 47274 Phone: 812-522-0524 | |
Sarah Elizabeth Ramey, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 357 Tanger Blvd Ste 201b, Seymour, IN 47274 Phone: 812-523-3700 | |
Virginia Stewart-kinney, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 411 W Tipton St, Seymour, IN 47274 Phone: 812-522-2349 | |
Dr. Stephanie Amber Burgess, DNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1171 W Tipton St, Suite D, Seymour, IN 47274 Phone: 812-524-8780 | |
Yvonne Carmela Lucas, MSN, RN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 113 N Chestnut St Ste 100, Seymour, IN 47274 Phone: 812-524-8388 |